Acrivon Therapeutics, Inc. Financials
This page shows Acrivon Therapeutics, Inc. (ACRV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Acrivon Therapeutics, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Acrivon Therapeutics, Inc. generates $0.82 in operating cash flow (-$63.7M OCF vs -$77.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Acrivon Therapeutics, Inc.'s EBITDA was -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.2% from the prior year.
Acrivon Therapeutics, Inc. reported -$77.9M in net income in fiscal year 2025. This represents an increase of 3.3% from the prior year.
Acrivon Therapeutics, Inc. earned $-2.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 15.1% from the prior year.
Cash & Balance Sheet
Acrivon Therapeutics, Inc. generated -$65.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 4.5% from the prior year.
Acrivon Therapeutics, Inc. held $41.5M in cash against $0 in long-term debt as of fiscal year 2025.
Acrivon Therapeutics, Inc. had 39M shares outstanding in fiscal year 2025. This represents an increase of 24.1% from the prior year.
Margins & Returns
Acrivon Therapeutics, Inc.'s ROE was -69.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 23.7 percentage points from the prior year.
Capital Allocation
Acrivon Therapeutics, Inc. invested $60.0M in research and development in fiscal year 2025. This represents a decrease of 6.3% from the prior year.
Acrivon Therapeutics, Inc. invested $1.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 39.7% from the prior year.
ACRV Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $13.6M-15.7% | $16.2M+5.0% | $15.4M | N/A | $18.9M+25.6% | $15.0M+31.0% | $11.5M | N/A |
| SG&A Expenses | $6.0M-6.6% | $6.5M+3.5% | $6.2M | N/A | $6.3M-2.1% | $6.4M+3.5% | $6.2M | N/A |
| Operating Income | -$19.7M+13.1% | -$22.6M-4.6% | -$21.7M | N/A | -$25.1M-17.3% | -$21.4M-21.3% | -$17.7M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$18.2M+13.2% | -$21.0M-6.7% | -$19.7M | N/A | -$22.4M-19.4% | -$18.8M-14.0% | -$16.5M | N/A |
| EPS (Diluted) | $-0.47+14.5% | $-0.55-7.8% | $-0.51 | N/A | $-0.59-13.5% | $-0.52+28.8% | $-0.73 | N/A |
ACRV Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $145.3M-8.4% | $158.6M-10.1% | $176.3M-10.3% | $196.6M-8.4% | $214.7M-6.9% | $230.6M+91.3% | $120.5M-12.8% | $138.3M |
| Current Assets | $130.4M-5.8% | $138.4M-8.5% | $151.3M-16.7% | $181.6M-3.9% | $189.0M+3.6% | $182.4M+62.6% | $112.1M-13.5% | $129.7M |
| Cash & Equivalents | $35.4M-15.5% | $41.9M+7.0% | $39.2M-1.7% | $39.8M-8.3% | $43.4M-5.6% | $46.0M+87.0% | $24.6M-31.7% | $36.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $16.7M+7.4% | $15.5M-2.6% | $16.0M-19.4% | $19.8M+11.3% | $17.8M+22.5% | $14.5M+15.8% | $12.5M-26.5% | $17.1M |
| Current Liabilities | $14.9M+10.9% | $13.4M-0.9% | $13.6M-21.3% | $17.2M+16.2% | $14.8M+31.3% | $11.3M+24.8% | $9.0M-32.0% | $13.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $128.6M-10.1% | $143.0M-10.8% | $160.4M-9.3% | $176.8M-10.2% | $196.9M-8.9% | $216.1M+100.1% | $108.0M-10.9% | $121.2M |
| Retained Earnings | -$255.9M-7.7% | -$237.7M-9.7% | -$216.7M-10.0% | -$197.0M-13.1% | -$174.1M-14.8% | -$151.7M-14.1% | -$132.9M-14.2% | -$116.4M |
ACRV Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.3M+26.1% | -$16.6M+15.0% | -$19.5M-12.5% | -$17.4M-0.2% | -$17.3M-24.6% | -$13.9M+18.6% | -$17.1M-38.1% | -$12.4M |
| Capital Expenditures | $899K+82.4% | $493K+750.0% | $58K-93.0% | $827K-16.4% | $989K+621.9% | $137K-83.2% | $815K-29.2% | $1.2M |
| Free Cash Flow | -$13.2M+22.9% | -$17.1M+12.7% | -$19.6M-7.7% | -$18.2M+0.7% | -$18.3M-30.4% | -$14.0M+21.6% | -$17.9M-32.4% | -$13.5M |
| Investing Cash Flow | $5.9M-69.6% | $19.5M+1.2% | $19.2M+33.3% | $14.4M-10.0% | $16.0M+118.2% | -$88.0M-1605.0% | $5.8M-71.5% | $20.5M |
| Financing Cash Flow | -$117K-20.6% | -$97K+71.7% | -$343K+47.0% | -$647K+57.0% | -$1.5M-101.2% | $123.3M+71815.1% | -$172K+91.4% | -$2.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ACRV Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -14.2%+0.5pp | -14.7%-2.4pp | -12.3% | N/A | -11.4%-2.7pp | -8.7%+6.6pp | -15.3% | N/A |
| Return on Assets | -12.6%+0.7pp | -13.3%-2.1pp | -11.2% | N/A | -10.4%-2.3pp | -8.2%+5.5pp | -13.7% | N/A |
| Current Ratio | 8.75-1.6 | 10.31-0.9 | 11.17+0.6 | 10.55-2.2 | 12.75-3.4 | 16.16+3.8 | 12.40+2.7 | 9.75 |
| Debt-to-Equity | 0.13+0.0 | 0.110.0 | 0.10-0.0 | 0.11+0.0 | 0.09+0.0 | 0.07-0.0 | 0.12-0.0 | 0.14 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Acrivon Therapeutics, Inc. profitable?
No, Acrivon Therapeutics, Inc. (ACRV) reported a net income of -$77.9M in fiscal year 2025.
What is Acrivon Therapeutics, Inc.'s EBITDA?
Acrivon Therapeutics, Inc. (ACRV) had EBITDA of -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Acrivon Therapeutics, Inc.'s return on equity (ROE)?
Acrivon Therapeutics, Inc. (ACRV) has a return on equity of -69.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Acrivon Therapeutics, Inc.'s free cash flow?
Acrivon Therapeutics, Inc. (ACRV) generated -$65.3M in free cash flow during fiscal year 2025. This represents a 4.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Acrivon Therapeutics, Inc.'s operating cash flow?
Acrivon Therapeutics, Inc. (ACRV) generated -$63.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Acrivon Therapeutics, Inc.'s total assets?
Acrivon Therapeutics, Inc. (ACRV) had $129.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Acrivon Therapeutics, Inc.'s capital expenditures?
Acrivon Therapeutics, Inc. (ACRV) invested $1.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Acrivon Therapeutics, Inc. spend on research and development?
Acrivon Therapeutics, Inc. (ACRV) invested $60.0M in research and development during fiscal year 2025.
What is Acrivon Therapeutics, Inc.'s current ratio?
Acrivon Therapeutics, Inc. (ACRV) had a current ratio of 7.69 as of fiscal year 2025, which is generally considered healthy.
What is Acrivon Therapeutics, Inc.'s debt-to-equity ratio?
Acrivon Therapeutics, Inc. (ACRV) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Acrivon Therapeutics, Inc.'s return on assets (ROA)?
Acrivon Therapeutics, Inc. (ACRV) had a return on assets of -60.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Acrivon Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Acrivon Therapeutics, Inc. (ACRV) had $41.5M in cash against an annual operating cash burn of $63.7M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Acrivon Therapeutics, Inc.'s Piotroski F-Score?
Acrivon Therapeutics, Inc. (ACRV) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Acrivon Therapeutics, Inc.'s earnings high quality?
Acrivon Therapeutics, Inc. (ACRV) has an earnings quality ratio of 0.82x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.